Navigation Links
CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Date:1/6/2011

in treatment resistant depression, and we are delighted that our Phase II trial is now enrolling patients," said Daniel Burch, MD, Chief Medical Officer of CeNeRx.  "The new formulation of TriRima has demonstrated excellent safety in multiple studies to date, and we believe that it has the potential to become the first agent to achieve the triple action efficacy of MAO inhibitor drugs without their limiting side effects."

The modified release formulation of TriRima has major advantages over the version used in earlier studies.  In addition to displaying excellent pharmacokinetic properties, the dosing frequency has been reduced to one tablet administered once or twice daily.

"TriRima addresses a large unmet medical need -- currently a substantial proportion of patients with major depression do not receive adequate relief from their therapy," noted Barry Brand, Chief Executive Officer of CeNeRx.  "TriRima has the potential to be the first option that provides these patients superior efficacy and a good safety profile as monotherapy, and we look forward to advancing the Phase II trial in the coming year."

CeNeRx will be presenting at the Biotech Showcase 2011 meeting at 11:00 AM PST on January 11.  The conference is being held January 10-12, 2011 at the Parc 55 Wyndham, San Francisco.   More information on the meeting can be found at www.ebdgroup.com/bts/index.php.

.

About CeNeRx BioPharmaCeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system.  CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression.  RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profil
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. CeNeRx BioPharma Completes $13 Million Series C Financing
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 The Pennsylvania State Police will ... 27, as part of National Prescription Drug Take-Back Day. ... Take-Back Day is a national initiative, conducted ... aimed at encouraging the public to dispose of expired, ... abuse and theft. From 10 a.m. to ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... Iowa , Sept. 23, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... a No Objection Letter (NOL) from Health Canada ... for its lead product candidate KP201 ... prodrug in development for acute moderate to moderately ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... Calif., Aug. 2, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following investor ... Conference Location: Intercontinental Hotel, Boston, MA Presentation ... Wedbush Life Sciences ...
... Mich., Aug. 2, 2011 Perrigo Company (Nasdaq: PRGO;TASE) today ... quarter fiscal 2011 on Tuesday, August 16 , 2011 at ... call at 10:00 a.m. (ET) hosted by Joseph C. Papa, ... call will be available live via webcast to interested parties ...
Cached Medicine Technology:
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Connie Casad ... medical practices to new office space at 12200 Park Central ... at the office will be Park Cities Aesthetics, Optimal Health ... , In announcing her move, Dr. Casad said, “The patients’ ... treatment they select, we want them to always feel like ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Avid collector Andrew ... 1967 The Doors Eagle Auditorium Seattle concert posters. The Doors ... “Break On Through” that year. The Seattle Eagles Auditorium concert ... “The Doors would return to Eagles Auditorium in November the ... is not known and comes in three colors. The poster ...
Breaking Medicine News(10 mins):Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2
... ... New York personal injury attorney, David Perecman. , ... New York, NY (PRWEB) July 14, 2009 -- Three workers, including a ... accident at a privately operated waste transfer plant in Jamaica, Queens. All three apparently ...
... , , ... Masimo (Nasdaq: MASI ), the inventor of Pulse ... 2009 Silver Medical Design Excellence Award in the general hospital devices ... award recognizes Rad-87,s excellence in medical technology engineering and design as ...
... Five hospital board members honored at annual conference ... Minn., July 14 Five Minnesota hospital ... member certification program. , , The ... issues, to hone their leadership skills and to develop governance best ...
... , , , , ... Inc. announced today that the Dakim(R) BrainFitness(TM) System has now been adopted ... their defenses against dementia and memory loss. Dakim has added 136 new ... brain training system provider in the senior care market. , ...
... Calif., July 14, 2009 A drug similar to one ... psoriasis has been found to rescue memory in mice exhibiting ... hope that a new treatment may be on the horizon ... cause of elderly dementia afflicting more than 5 million people ...
... , , ATLANTA , ... of EyeSite(TM) self-service vision testing kiosks, announced today it will team ... educational experience featured in the kiosks. The EyeSite kiosks contribute ... vision assessments and driving consumers to local eye care professionals for ...
Cached Medicine News:Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 2Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 4Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 2Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 3Health News:Drug rescues memory lost to Alzheimer's disease 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 3
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: